Synthetic Biologics (SYN) Sees Large Volume Increase

Shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) saw unusually-strong trading volume on Monday . Approximately 932,833 shares traded hands during trading, an increase of 196% from the previous session’s volume of 315,450 shares.The stock last traded at $0.91 and had previously closed at $0.82.

A number of research analysts recently commented on SYN shares. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Synthetic Biologics in a research note on Thursday, August 9th. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.25 price target for the company in a research report on Tuesday, August 14th.

Synthetic Biologics (NYSEAMERICAN:SYN) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.40) by $0.35.

ILLEGAL ACTIVITY WARNING: “Synthetic Biologics (SYN) Sees Large Volume Increase” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at

About Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

Featured Story: Bear Market – How and Why They Occur

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.

Leave a Reply